Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Novartis stands on the brink of launching the first innovative treatment for hypertension in over a decade, in the form of Rasilez (aliskiren), thanks to the efforts of the drug's development partner, Speedel. This vindicates the risk Speedel took back in 1998 when it set out to build a business based on big pharma cast-offs, something many believed was doomed to fail.
Published By Datamonitor
|
10 Mar 2006 |
|
CommentWire
|
Speedel and Novartis' Rasilez, the first, orally available direct renin inhibitor, has demonstrated in a phase III trial that it is a safe addition to the current antihypertensive armamentarium. The results clearly show that the novel agent is a viable treatment option, but whether this clinical success can translate into commercial potential remains to be seen, as further hurdles await.
Published By Datamonitor
|
18 May 2006 |
|
CommentWire
|
After failing to receive suitably attractive offers, Serono's controlling shareholder has ended discussions concerning a sale of the company, opting instead to focus on growth via acquisitions. Although this shift in strategy has startled investors, it could prove a good move in the long term, if it can sufficiently strengthen Serono's relatively weak pipeline.
Published By Datamonitor
|
11 Apr 2006 |
|
CommentWire
|
A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.
Published By Datamonitor
|
02 Aug 2006 |
|
CommentWire
|
Roche's acquisition of Disetronic looks set to boost its presence in the diabetes market. But its enthusiasm will be tempered by news that the spin-off of its vitamin business will reap lower rewards than expected, while further funds must be set aside to settle price rigging claims. Even so, Roche and Disetronic will enjoy some valuable synergies.
Published By Datamonitor
|
12 Feb 2003 |
|
CommentWire
|
Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.
Published By Datamonitor
|
14 Oct 2010 |
|
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
CommentWire
|
JTT-705, which Roche is to license from Japan Tobacco, is a novel anti-dyslipidemic that will further enhance the company's cardiovascular risk factor offering. This latest move could ultimately place Roche in a potentially advantageous position in the growing metabolic syndrome market, though it marks only the start of a long process to increase its currently meager offering in this field.
Published By Datamonitor
|
21 Oct 2004 |
|
CommentWire
|
Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.
Published By Datamonitor
|
20 Jul 2005 |
|
CommentWire
|
The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.
Published By Datamonitor
|
30 Mar 2005 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.